# 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Source: https://onco.cc/trials/nct07314723/  
OnCo record `nct07314723` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer is a phase 2 interventional study registered as NCT07314723 by Mabwell (Shanghai) Bioscience Co., Ltd., with 90 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: 9MW2821 and Toripalimab Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07314723
- Phase: 2
- Setting: A Single Arm, Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07314723: https://clinicaltrials.gov/study/NCT07314723

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct07314723.json